Trial of JYB1904 in Patients With Allergic Asthma

Phase IIa Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety of JYB1904 in Patients With Allergic Asthma

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Inclusion Criteria:

• Able to provide written informed consent voluntarily;
• Aged 18-75 years, weight ≥ 40 kg, male or female;
• Diagnosed Allergic asthma.

Exclusion Criteria:

• Prior exposure to anti-IgE therapy within 1 year;
• Allergic to anti-IgE biologics;
• Current smokers, or quit smoking within 1 year;
• Combined with other non-allergic diseases that cause IgE elevation；
• History of malignancy, autoimmune diseases, Immune complex mediated diseases, Hypereosinophilic syndrome;
• Other conditions unsuitable for the trial judged by the investigator.